Patient Registries in Idiopathic Pulmonary Fibrosis
- PMID: 31034241
- PMCID: PMC6635784
- DOI: 10.1164/rccm.201902-0431CI
Patient Registries in Idiopathic Pulmonary Fibrosis
Abstract
Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established. These registries are collecting a wealth of longitudinal data on thousands of patients with this rare disease. The data collected in these registries will be complementary to data collected in clinical trials because the patient populations studied in registries have a broader spectrum of disease severity and comorbidities and can be followed for a longer period of time. Maintaining the quality and completeness of registry databases presents administrative and resourcing challenges, but it is important to ensuring the robustness of the analyses. Data from patient registries have already helped improve understanding of the clinical characteristics of patients with IPF, the impact that the disease has on their quality of life and survival, and current practices in diagnosis and management. In the future, analyses of biospecimens linked to detailed patient profiles will provide the opportunity to identify biomarkers linked to disease progression, facilitating the development of precision medicine approaches for prognosis and therapy in patients with IPF.
Keywords: biomarkers; interstitial lung diseases; observational study; pulmonary fibrosis.
Comment in
-
Reply to Nett et al.: Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries.Am J Respir Crit Care Med. 2020 Feb 15;201(4):496-497. doi: 10.1164/rccm.201910-2010LE. Am J Respir Crit Care Med. 2020. PMID: 31664851 Free PMC article. No abstract available.
-
Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status.Am J Respir Crit Care Med. 2020 Apr 15;201(8):1014-1015. doi: 10.1164/rccm.201911-2275LE. Am J Respir Crit Care Med. 2020. PMID: 31940215 Free PMC article. No abstract available.
-
Overlooked Role of Histopathology in Evaluations for Occupational/Environmental Exposures.Am J Respir Crit Care Med. 2020 Jun 15;201(12):1581. doi: 10.1164/rccm.201911-2195LE. Am J Respir Crit Care Med. 2020. PMID: 32119783 Free PMC article. No abstract available.
-
Reply to Sanyal et al.: Overlooked Role of Histopathology in Evaluations for Occupational/Environmental Exposures.Am J Respir Crit Care Med. 2020 Jun 15;201(12):1581-1583. doi: 10.1164/rccm.202002-0367LE. Am J Respir Crit Care Med. 2020. PMID: 32119791 Free PMC article. No abstract available.
References
-
- Council of the European Union. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) Official Journal of the European Union. 2009;C151:7–10.
-
- Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50:1701209. - PubMed
-
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis. Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
-
- Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous